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2Abstract
Respiratory illness is a common manifestation of HIV infection. The availability of effective
antiretroviral therapy (ART) has changed the pattern of respiratory ill-health experienced by people
living with HIV (PLWH). Among populations with good access to ART, opportunistic respiratory
infections such as Pneumocystis jirovecii pneumonia (PCP) are becoming less frequent. However,
there is evidence to suggest that these populations may be at greater risk of serious non-AIDS illness
including chronic respiratory disease. Although there is remaining uncertainty about the extent to
which HIV represents an independent risk-factor for respiratory illness in individuals with a
suppressed HIV viral load and immune reconstitution, in many settings PLWH have greater exposure
to risk factors for respiratory illness (in particular tobacco smoking), which contribute to this burden
of disease. As HIV-positive populations age, management of these conditions will therefore become
increasingly important. Healthcare services need to manage this growing burden of chronic
respiratory illness and provide access to preventative measures including smoking cessation and
immunisation against vaccine-preventable respiratory infections in a way that is appropriate to the
populations served.
3Introduction
Since the early reports in the 1980’s of Pneumocystis jirovecii pneumonia (PCP) as a common AIDS-
defining illness, HIV infection has had an enduring relationship with respiratory disease. Without
effective antiretroviral therapy (ART), people living with HIV (PLWH) are at greatly increased risk of
pulmonary infections. (1) As well as PCP, bacterial pneumonia and tuberculosis (TB) are both
common. ART can suppress HIV replication and enable immune reconstitution such that the
incidence of pulmonary infection falls to the background level of the HIV uninfected. (2) In settings
with good access to ART, this results in PLWH living considerably longer. With continued HIV
transmission events and subsequent new infections, there is an expanding population who are now
starting to age. Being HIV infected does not protect from the comorbidities associated with ageing,
and may even promote them. As a result, we are now seeing a change in the pattern and tempo of
respiratory illnesses that occur in PLWH. In this article, we review the bi-directional interaction
between chronic HIV infection and respiratory illness.
Respiratory symptoms and HIV
Respiratory symptoms are common in PLWH and appear to be more frequent than in HIV negative
populations. A systematic review and meta-analysis of studies reporting these in PLWH compared to
HIV negative groups found a significantly higher prevalence in the former. The difference narrowed
in populations with access to antiretroviral therapy, such that in resource rich populations with
access to ART the pooled Odds Ratio (OR) for reported breathlessness was 1.39 (95% CI 1.11-1.73).
(3) Figure 1 demonstrates the collated data from a number of such studies that have included
information on self-reported breathlessness using the MRC score and compared PLWH with HIV
negative controls.
4Figure 1: Forest plot showing odds ratio of having MRC score ≥2 in HIV positive compared to HIV
negative groups. MRC 2 = breathless on an incline (Adapted from Brown et al)(3)
It should be noted, however, that studies evaluating respiratory symptoms in PLWH often cannot
adjust for important confounding factors such as tobacco smoking (which is more common in HIV
positive populations), and have often included a higher proportion of individuals who are not
virologically suppressed despite using ART. Therefore, data from earlier reports may not be
representative of a contemporary HIV positive population in many parts of the world.
A recent study from London of 197 HIV positive and 93 HIV negative participants specifically
evaluated the prevalence of respiratory symptoms with the St George’s Respiratory Questionnaire
(SGRQ) and Medical Research Council (MRC) dyspnoea scale. It found a greater frequency of
respiratory symptoms in PLWH, with a median SGRQ of 12 (IQR 6-25) vs 6 (2-14) in controls,
p<0.001. (4) As the minimum clinically important difference between groups is usually regarded as
four, (5) this suggests that the PLWH had more reported symptoms. In line with this, 47% of the HIV
positive group had MRC scores ≥2 (breathless going up an incline) compared to 24% in the HIV 
negative controls (p=0.001). After adjustment for confounding variables such as age, gender,
smoking, Body Mass Index (BMI) and depression, this difference persisted with the adjusted OR of
an MRC score of ≥2 being 2.45 (95% CI 1.15-5.20, p=0.02).  
5Although relatively few studies have measured respiratory symptoms in PLWH and compared these
to matched HIV negative controls, current evidence suggests that symptoms such as cough and
breathlessness are more common in HIV. There are likely to be multiple contributing causes
including; higher rates of smoking tobacco and other substances, and increased non-communicable
cardiovascular and respiratory illness. Despite attempts to control for this, it cannot be discounted
that PLWH have a lower threshold to report symptoms, and so appear to have a greater symptom
burden. The evidence for this is limited though factors such as higher depression scores in PLWH
may contribute. (4)
Infectious pulmonary disease in contemporary HIV populations
High rates of HIV suppression in the current HIV infected populations with access to ART have led to
significant reductions in the morbidity and mortality associated with respiratory infection. However,
a number of studies have concluded that the risk is still greater than in controls.
Data from the US Veterans care service reported by Crothers et al (6) showed that rates of bacterial
pneumonia, PCP and TB were still significantly greater in PLWH (28, 9.9 and 4.5/1000 person years
respectively) than in matched HIV negative controls (5.8, 0.02 and 0.6/1000 person years). However,
only 65% of this population were using ART, and the median CD4 count was 264 cells/µL, which
would be regarded as at least moderately impaired immunity; and some way below the immune
reconstitution that is generally achieved by increased ART coverage with good medication
adherence.
Further data from the Womens’ Interagency HIV study (WIHS) (a cohort developed in 1994) (7) and
the Multicentre AIDS Cohort Study (MACS) (a cohort developed in 1984) (8) again demonstrated a
higher risk of bacterial pneumonia in PLWH, although this has fallen significantly compared to the
pre-ART era. (9) For example, the MACS cohort reported a current adjusted OR for bacterial
pneumonia in PLWH compared to controls of 4.14, whereas pre-ART this was 21.8. Of interest, the
6WIHS study showed a higher adjusted OR of 9.55 for bacterial pneumonia in HIV positive women
with access to ART compared to matched controls. It is uncertain if this is due to innate biological
factors, or reflects a common theme of worse access to care for women.
In contrast, data from the EuroSIDA collaboration of 18,000 patients in 36 predominantly European
countries from 2006-2011 found a significantly lower incidence of bacterial pneumonia in the HIV
positive population of 5.36/1000 person years. (10) The mean CD4 count in this population was 457
cells/µL and there were very low rates of severe bacterial infections including pneumonia in the
subgroup with CD4 counts >500 cells/µL (generally recognised as a normal CD4 count). Although
there was no HIV negative group in the study to allow direct comparison, other workers have
estimated the incidence of bacterial pneumonia in the general population to lie between 5 -11/1000
person years. (11-13)
Viral infections are a common cause of acute respiratory illness in all populations, and PLWH may be
more susceptible to such infections, or more likely to develop severe disease compared to those
without HIV. Clinical guidelines in the USA, UK and Europe therefore recommend annual
immunisation against Influenza for all PLWH. (14,15) There is however somewhat conflicting
evidence as to whether PLWH are more likely to suffer severe viral infection. Cohen et al (16)
demonstrated an increased mortality in acute influenza infections in PLWH compared to HIV
negative patients in South African and American populations. However, this excess mortality was
reduced in the USA once ART was available. (16) Subsequent studies during the H1N1 pandemic
have shown no increase in deaths in HIV positive individuals. (17)
There are little data directly comparing HIV suppressed PLWH using ART to HIV negative controls. It
is likely that this will be available in the coming years, and will enable us to determine the current
impact and significance of respiratory infection in a contemporary HIV population.
Case Vignette 1 and Figure 2 to be inserted here.
7Non-communicable respiratory disease
Asthma
It is unclear whether PLWH are more or less likely to have asthma. In a cross-sectional analysis of
223 HIV infected participants, Gingo et al reported a physician diagnosis of asthma in 20.6%. (18)
However, in the Veterans Ageing Cohort Study (VACS) (19) the prevalence of asthma was
considerably lower (and in fact less than in an HIV negative control group: 2.0% versus 2.4%
respectively, p<0.001), whilst the incidence of new diagnoses of asthma was the same in the two
populations. It is likely that the difference in the two US-based studies reflects the populations under
test (eg risk for HIV, use of ART, age) and also the methods used to classify a patient as having
asthma. For example, compared to the definition used by Gingo, the VACS study relied on an asthma
ICD-9 coding having been recorded once as an inpatient or twice as an outpatient. There are little
data regarding the effect of HIV status on asthma control.
An asthma study investigating a US Veteran’s Administration population of almost 26,000
(containing <1%, n = 166, PLWH) reported a significant increase in all-cause mortality in HIV patients
with asthma aged 18-45 (OR 3.64, 95% CI 1.34-9.87). (20) Whilst this may have resulted from
immunocompromise due to HIV (the study was performed when ART was not widely used), there
was also a significantly increased incident rate ratio (IRR) for asthma-related hospitalisations in
PLWH aged <65 [age 18-45, IRR 2.13 and age 45-65, IRR 1.91], suggesting that PLWH had more
episodes of asthma resulting in admission to hospital (which would imply that these events were
more severe). However, the small number of PLWH in the overall study argues for more focused
work in this area.
Several studies after the advent of ART have shown that asthma is more common in children with
vertically acquired HIV. (21-23) Data from the National Institute of Health (NIH) Women and Infants
transmission study (WITS) (24) demonstrated an increased cumulative incidence at age 13.5 years of
8asthma medication usage (as a proxy measure of asthma diagnosis) of 33.5% in HIV positive children
on ART compared to 11.5% in HIV positive children not on ART. It has been suggested therefore, that
the immune reconstitution associated with ART results in asthma symptoms, though the evidence
for this is weak.
Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) has the potential to become a major comorbidity in
PLWH. This may in part be a consequence of a higher prevalence of tobacco and recreational drug
inhalation in many HIV positive populations, though also reflects the rising median age of most HIV
cohorts using ART, and possibly the impact of chronic HIV infection itself. Crothers et al (25)
reported that in the VAC study, after adjusting for age, race, smoking intensity, injection drug use
and alcohol misuse, there was still an increased odds of having a diagnosis of COPD in the HIV
positive group compared to HIV negative controls [OR of ICD-9 coded diagnosis of COPD 1.47 (95% CI
1.01-2.13) and for a self-reported diagnosis of COPD 1.58 (95 % CI 1.14-2.18)]. Further data from a
larger sample of this cohort (33,000 HIV positive and over 66,000 HIV negative individuals)
demonstrated a higher incidence of COPD in the PLWH (20.3 versus 17.5 /1000 person years,
p<0.001). The incidence was significantly greater in people with higher HIV load and lower in those
who were taking ART at baseline, indicating that disease control may have an influence on the
diagnosis and progression of COPD. Attia found that HIV infection was an independent risk factor for
radiological evidence of emphysema (defined as over 10% involvement on CT chest scans) in
analyses adjusted for smoking rate (OR 2.24, 95% CI 1.12-4.48). (26)
In the ALIVE cohort (27) of current and former injection drug users in Baltimore (in which
approximately 30% of subjects are HIV positive), despite the HIV positive group having a lower
baseline FEV1 and FVC, prospectively measured spirometry fell at the same rate over 3 years in HIV
positive and HIV negative participants. However, when the HIV positive group was stratified by
9whether or not HIV suppression was achieved on ART, and also blood CD4 count above and below
100 cells/µL, there was a faster decline in spirometry in those with markers of worse immunity.
Although this implies that poorly controlled HIV may be driving a fall in lung function, the Strategic
Timing of Antiretroviral Treatment (START) trial (28) (which randomised 1026 PLWH with CD4 counts
above 500 cells/µL to immediate or deferred ART) evaluated the rate of spirometric change in a
pulmonary sub-study and found no significant difference between the groups in FEV1 decline over a
two year follow up. Additionally, this appeared to be the same for smokers and non-smokers. It
should be noted that the populations within the ALIVE and START studies are different, with the
former having evidence of more advanced immunosuppression prior to study entry (25% had a
blood CD4 count <200 cells/µL) compared to START subjects. This may in part explain the differences
in results.
It is tempting to speculate that HIV infection itself may play a role in the development of COPD. Early
data (29) suggesting that an accelerated form of emphysema in HIV infected smokers was dramatic
and common appears to be less of an issue than originally thought. However milder CT-diagnosed
emphysema has been reported in up to 25% of US adults. Unlike non-specific mild fibrotic changes
(which in the same study were present in almost one third of participants), trace emphysema does
not appear to be related to progressive immunocompromise. (30)
A consistent finding from studies is that carbon monoxide diffusing capacity (DLCO) is reduced out of
proportion to spirometry. (31) This appears to be associated with symptoms such as breathlessness,
cough or sputum. (32) What underlies the lower DLCO is likely to be multifactorial, though it is of
relevance that advanced HIV infection is associated with mucosal CD4 cell depletion and a CD8
alveolitis, and this appears to be reversed by ART. (33) Whether drug therapy can slow or reverse
clinically significant airway and alveolar abnormalities is less clear.
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In summary, there are a number of studies recognising that COPD and lung function changes are
common in HIV positive cohorts with no previous history of significant respiratory disease. There are
less data investigating why this occurs, the precise contribution made by HIV infection and ART,
compared to associated behavioural factors such as smoking, or whether it can be managed in part
through immune modulation.
Pulmonary Hypertension
The association between HIV and pulmonary arterial hypertension (PAH) was first noted in the late
1980s and studies from the early 1990s before the ready availability of ART reported a prevalence of
PAH in PLWH as high as 0.5%. (34) It is known that survival is worse in HIV-PAH patients not using
ART compared to HIV negative patients with PAH, (35) and PLWH without PAH, (36) and that PAH is
an independent risk factor for death in PLWH. (37) The predominant symptom is rapidly progressive
breathlessness and the median duration to diagnosis from onset of symptoms is 6 months. ART has
significantly improved HIV associated mortality but the prevalence of HIV-PAH in some studies has
remained static at 0.5%. (38) This is still many times higher than the general population where the
prevalence is recognised to be 10-52 cases per million (0.001 to 0.005%). (39) Opravil et al (40) in
the Swiss HIV cohort have shown a reduced incidence of HIV-PAH from 0.21% in 1995 to 0.03% in
2006 indicating that ART may have some effect. However, this significant reduction has not been
reproduced elsewhere.
Case Vignette 2 and Figure 3 to be inserted here
Lung Cancer
Lung cancer is now the leading cause of cancer deaths in PLWH. (41-43) This may be largely due to
increased rates of smoking in this population, though HIV infection does appear to be an
independent risk factor for lung cancer. (44) PLWH appear to develop lung cancer at a younger age
than HIV negative individuals. (45)
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Hessol et al (46) studied participants from the Women’s Interagency HIV study (WIHS) and
Multicenter AIDS Cohort study (MACS) cohorts. All but one incident lung cancer occurred in current
or ex-smokers so further analysis was limited to those who had smoked ≥100 cigarettes prior to 
baseline assessment. When the two cohorts were combined, HIV infection was significantly
associated with lung cancer incidence (IRR 2.64, 95% CI 1.43-5.21). The unadjusted results from the
MACS cohort also suggested an association between incident lung cancer diagnosis and lower blood
CD4 counts, higher peak HIV load, and a prior AIDS diagnosis. This does not distinguish between a
direct HIV effect and possible confounding variables. However, multivariable analysis of the
combined data (1984-2011) indicated that older age, less education, a prior AIDS pneumonia
diagnosis and ≥10 pack year smoking history were independently associated with a higher IRR of 
lung cancer.
Treatment for lung cancer in the HIV population lacks a strong evidence base as often HIV infection
has been an exclusion criterion for clinical trials. A large population based study of 156,930 lung
cancer patients (including 337 PLWH) reported to the Texas cancer registry from 1995-2009 (47)
demonstrated that HIV infected patients with non-small cell lung cancer (NSCLC) were less likely to
receive any cancer treatment than HIV uninfected individuals (60.3% v 77.5%, OR 0.39 95% CI 0.3-
0.52) even after adjustment for year of diagnosis, age, sex, race, stage and histological subtype. HIV
positive patients were also less likely to be surgically treated for local disease. Lung cancer mortality
was higher in PLWH (Hazard ratio 1.34 98% CI 1.15-1.56) and HIV positive patients were more likely
to present with disseminated disease. This study was limited by lack of data on CD4 count, use of
ART, socioeconomic status, medical insurance performance status and comorbid illness, all of which
may affect access to, and suitability for, cancer treatment. The full explanation for this disparity is
likely to be multifactorial and may include lack of specific guidelines for HIV- related lung cancer,
concern about drug interactions with ART and possibly a historical belief that HIV infection
significantly reduces Performance Status. This serves to highlight the need for joined up specialist
care, multiprofessional working, sustained healthcare worker and public education programmes.
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As PLWH on ART now have a life expectancy similar to the general population and minimal
impairment of Performance Status, it is likely that more data will become available on lung cancer
treatment in this group.
Sleep disordered breathing
Fatigue and daytime somnolence are commonly reported symptoms in PLWH. There can be
significant overlap between the description of these and breathlessness. There is conflicting
evidence regarding the contribution sleep disordered breathing makes to these symptoms.
Cross-sectional data from VACS reported a prevalence of obstructive sleep apnoea (OSA) in HIV
positive individuals of 3.9% compared to 12.4% in an HIV negative population. (48) Patil found an
extremely high rate of sleep disordered breathing in males within MACS. (49) This was present in
PLWH using ART, those not on ART and the HIV negative group (71%, 74% and 87% respectively).
The authors concluded that there may have been an element of reporting bias considering the high
prevalence in all groups. Gingo, using data from MACS and WIHS, found that the prevalence of sleep
apnoea was similar in HIV infected men and women when compared to the uninfected group (<5%
for both groups). (50) When this data were adjusted for measures such as age, race, BMI and
smoking status there was an increased prevalence of sleep apnoea in the PLWH in both cohorts
compared to the HIV negative group with a prevalence ratio (PR) of 1.42 (95% CI 1.1-1.84, p=0.01) in
MACS and 2.10 (95% CI 1.31-3.36, p=0.002) in WIHS. Of note, one of the major acknowledged risks
for OSA, raised BMI, was no more prevalent in the HIV population. Other possible factors that might
contribute to OSA include upper airway abnormalities due to tonsillar and adenoid hypertrophy, plus
the adverse effects of ART and other medication that can cause myopathy and abnormal body fat
redistribution (lipohypertrophy).
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As with so many aspects of HIV related respiratory disorders, more work is required to better
understand the relationship between HIV and sleep disordered breathing/OSA, fatigue and
somnolence; and how specific therapy may improve these symptoms.
Improving the respiratory health of people living with HIV
The extent to which HIV is an independent risk factor for respiratory illness in individuals using
effective antiretroviral therapy is uncertain. There is a need for more high-quality studies with well-
matched HIV negative controls in both adults and children. These should seek to answer specific
questions about the “natural history” of respiratory illness in contemporary populations, and also
test out potentially effective interventions that will reduce respiratory and associated morbidities. A
good example of this is the need to ensure that there is maximal and ongoing, effective ART usage in
all people living with HIV. This calls for improved access to healthcare in both resource rich and poor
environments.
In many settings PLWH are at greater risk of respiratory ill health due to higher exposure to known
drivers such as tobacco smoke. For example, in European and North American studies, PLWH are
significantly more likely to smoke than the general population. (51) They may also be less likely to
quit. (52) There is a need, therefore, to understand how services can be developed to help people
who want to stop smoking. Unfortunately, not only is this often a low priority for HIV services, but
also the current models of care provision may be unsuitable. For example, whilst PLWH smoking
rates are apparently high, they are in fact similar to HIV negative matched controls, suggesting that
the “message” needs to be directed “upstream” of HIV care if we are to achieve good quit rates. (4)
As well as addressing the frequency of tobacco smoking and recreational drug use, respiratory
health can be maintained by ensuring access to immunisations against vaccine-preventable
respiratory illness such as Pneumococcal pneumonia and influenza. Both of which are recommended
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for PLWH, (53, 54) with evidence of reasonable uptake in the UK. (55) It is important, however, to
ensure that the provision of these immunisations meets the needs of the HIV positive population
and so maximises their impact. (56)
Although the risk of TB is significantly reduced by the provision of ART, (2) PLWH remain at greater
risk of TB than the general population, in particular those who have migrated from high TB incidence
settings. Current guidelines provide differing advice regarding who should be screened for latent TB
infection and offered preventive treatment. Also, the changing demographics of TB in many,
generally resource rich locations mean that current guideline recommendations soon may not be
cost-effective. (57) There is a need to improve the evidence base supporting preventative strategies
for TB for PLWH. Improved diagnostic tests with a better ability to predict who is at risk of
developing TB than the currently available immune-based tuberculin skin tests and TB interferon
gamma release assays would significantly improve the benefit and cost-effectiveness of such testing.
Lung cancer screening in PLWH is potentially useful. The National Lung Screening Trial (58) in the
USA enrolled 53,454 current or former smokers aged 55-74 (≥30 pack years’ history) without 
symptoms or signs of lung cancer, and unknown HIV status. It showed that annual low dose helical
CT screening led to a relative reduction in mortality of lung cancer of 20% (95% CI 6.8-26.7, p=0.004)
compared to annual screening by chest radiograph. It is perhaps then intuitive that CT screening in
HIV patients with higher risk of lung cancer might reduce mortality. A multicentre feasibility single CT
study in France (59) of 442 HIV positive smokers (≥20 pack years) with median age 49.8 years and a 
nadir CD4 count ≤350 cells/µL found a positive CT result (defined as a significant nodule, adenopathy 
or endobronchial image) in 94 (21%). 15 went on to have further invasive procedures, without
significant complication, and lung cancer was diagnosed in 10 (2.3%), of which 9 had an abnormal
baseline scan. Six of these were diagnosed at early stages and eight patients were aged less than 55
years (and hence would not have been assessed if using the National Lung Screening Trial criteria).
The number of screening tests to detect one cancer was 49, which compares favourably with general
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population screening. Further work is required to better understand the possible benefits of lung
cancer screening, including which patients are at greatest risk for lung cancer and hence would
benefit most from a screening programme, the frequency of repeat CT imaging in people with
initially normal scans and what to do with the inevitably large number of non-specific pulmonary
nodules identified in PLWH.
The bringing together of existing population-based respiratory health programmes such as smoking
cessation, pulmonary rehabilitation, home oxygen, sleep and home ventilation services and lung
cancer MDT management, with potentially stand-alone HIV care providers is an important
component of long term, high quality HIV-related respiratory disease management and requires
planning.
Conclusions
Improving and maintaining respiratory health is an important part of care for PLWH. The provision of
ART has led to a change in the epidemiology of respiratory disease in this population with a
reduction in acute opportunistic respiratory infections and a growing burden of chronic non-
communicable respiratory disease. This presents challenges for the provision of HIV healthcare
services, which now have to manage acute respiratory illnesses and also offer long term effective
public health measures such as tobacco control, immunisations for vaccine-preventable infections,
and the complexity of multiple non-AIDS comorbidities alongside HIV care.
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Figure 1: Forest plot showing odds ratio of having MRC score ≥2 in HIV positive compared to HIV
negative groups. MRC 2 = breathless on an incline (Adapted from Brown et al )(3)
Vignette 1:
48 year old male ex-smoker with a history of advanced HIV infection, variable adherence to
antiretroviral therapy (ART) and a myocardial infarction with stent insertion age 43,
presented with cough, sputum and breathlessness. Mycobacterium xenopi was isolated from
multiple sputum samples. CT chest demonstrated a right upper lobe cavity with associated
soft tissue change plus marked emphysema (Figure). Improved ART adherence resulted in
no further positive mycobacterial cultures. Symptom improvement required regular
bronchodilators plus pulmonary rehabilitation.
Figure 2: Coronal image from a CT chest demonstrating extensive emphysematous change




areas in predominantly mid
and upper zone distribution)
Vignette 2:
57 year old HIV positive female smoker, undetectable HIV load and good blood CD4 counts,
presented with a short history of mid-thoracic back pain. CT chest demonstrates necrotic
right hilar and mediastinal lymph nodes plus a right upper lobe nodule (Figure).
Bronchoscopy confirmed the diagnosis of small cell lung cancer.
Figure 3: Coronal image from a CT chest demonstrating a right upper lobe nodule and large
volume mediastinal and right hilar lymphadenopathy as labelled.
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Necrotic
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nodes
